Tg Therapeutics (TGTX) Raw Materials (2023 - 2025)

Tg Therapeutics' Raw Materials history runs 3 years deep, the most recent figure standing at $4.1 million for Q3 2025.

• On a quarterly basis, Raw Materials rose 134.08% year-over-year to $4.1 million in Q3 2025; TTM through Sep 2025 was $4.1 million, a 134.08% increase from a year earlier, with the FY2024 full-year figure at $28.2 million, up 327.7% from the prior year.
• Raw Materials retreated to $4.1 million in Q3 2025 per TGTX's latest filing, from $4.1 million in the prior quarter.
• Across five years, Raw Materials topped out at $28.2 million in Q4 2024 and bottomed at $24000.0 in Q1 2023.
• The 3-year median for Raw Materials is $1.7 million (2024), against an average of $4.9 million.
• Biggest YoY gain for Raw Materials was 7129.17% in 2024; the steepest drop was 41.21% in 2024.
• Year by year, Raw Materials stood at $6.6 million in 2023, then soared by 327.7% to $28.2 million in 2024, then sank by 85.58% to $4.1 million in 2025.
• Per Business Quant, the three latest TGTX Raw Materials figures stand at $4.1 million (Q3 2025), $4.1 million (Q2 2025), and $4.1 million (Q1 2025).